Array BioPharma (ARRY) Posts Mixed Q3 Results
Tweet
Share
E-mailGet Alerts ARRY Hot Sheet
Price: $8.54 +6.75%
EPS Growth %: -48.0%
Financial Fact:
Research and development for proprietary programs: 46.56M
Today's EPS Names:
OCCI, MAYS, CRMT, More
EPS Growth %: -48.0%
Financial Fact:
Research and development for proprietary programs: 46.56M
Today's EPS Names:
OCCI, MAYS, CRMT, More
Join SI Premium – FREE
Array BioPharma, Inc. (Nasdaq: ARRY) reported Q3 loss of $0.20, $0.05 better than the analyst estimate of ($0.25). Revenue for the quarter came in at $17.8 million versus the consensus estimate of $19.58 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- ARRAY Technologies Launches DuraTrack D2S™ Tracker, Bringing Differentiated Features of ARRAY’s Trusted DuraTrack System to Dual Row Format Internationally
- Kroger meets earnings expectations, revenue tops estimates
- Jabil (JBL) Tops Q3 EPS by 8c, Offers Guidance
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
